Medy-Tox Inc.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureMedy-Tox was founded on May 2, 2000 and listed on KOSDAQ on January 16, 2009, engaging in research, manufacturing, and sales of Clostridium botulinum toxin type A biopharmaceuticals. Its flagship product Meditoxin(R) (Neuronox(R)) is joined by Innotox(R), the world's first liquid-type botulinum toxin type A product, Coretox, and the Neuramis(R) HA filler series. In its 26th fiscal year, consolidated revenue was about KRW 247.3 billion, with Meditoxin and other core products accounting for approximately 87% and medical devices and services about 13%, while the company exports Neuronox(R) and the Neuramis(R) series to around 30 countries from its Ochang and Osong, Cheongju production facilities.
Products & technology
- Meditoxin® / Neuronox®Botulinum toxin type A pharmaceutical (flagship product)
- Innotox®World's first liquid-type botulinum toxin type A pharmaceutical
- CoretoxBotulinum toxin pharmaceutical using non-animal excipients (L-methionine, polysorbate)
- Neuramis® seriesExport product (aesthetics market, HA filler line)
Regulatory approvals
data.go.kr10 Korean MFDS drug approvals · 2006–2025 / 11 Korean MFDS device approvals · 2011–2019
- MFDS drugNUVIJU Inj.(Cholic acid)2025-09-19Drug · Prescription · Approval202502484
- MFDSGraft/prosthesis, biomaterial2019-08-26Product approval · Class 4제허 19-561 호
- MFDSDressing, adhesion barrier2019-07-31Product approval · Class 3제허 19-512 호
- MFDS drugMEDYTOX ADETRI INJ2017-09-08Drug · Prescription · Notification201707024
- MFDS drugMEDYTOX HYALASE INJ2017-09-07Drug · Prescription · Notification201706998
- MFDS drugMEDYTOX GLUTA INJ2017-09-07Drug · Prescription · Notification201707005
- MFDS drugCoretox Inj.2016-06-24Drug · Prescription · Approval201603891
- MFDSGraft/prosthesis, biomaterial2014-12-09Product approval · Class 4제허 14-2923 호
- MFDS drugInnotox Inj.2013-12-11Drug · Prescription · Approval201310633
- MFDS drugMeditoxin Inj. 150U2013-10-15Drug · Prescription · Approval201309732
- MFDSGraft/prosthesis, biomaterial2013-05-16Product approval · Class 4제허 13-871 호
- MFDSGraft/prosthesis, biomaterial2012-11-21Product approval · Class 4제허 12-1480 호
Show 9 more
- MFDSGraft/prosthesis, biomaterialRevoked2012-10-29Product approval · Class 4제허 12-1370 호
- MFDSGraft/prosthesis, biomaterial2012-10-29Product approval · Class 4제허 12-1369 호
- MFDSGraft/prosthesis, biomaterial2012-10-29Product approval · Class 4제허 12-1368 호
- MFDSGraft/prosthesis, biomaterial2012-02-22Product approval · Class 4제허 12-216 호
- MFDSGraft/prosthesis, biomaterial2011-11-16Product approval · Class 4제허 11-1262 호
- MFDSGraft/prosthesis, biomaterial2011-10-10Product approval · Class 4제허 11-1112 호
- MFDS drugMEDITOXIN Inj.2010-02-24Drug · Prescription · Approval201001655
- MFDS drugMeditoxin Inj. 200U2009-03-31Drug · Prescription · Approval200902348
- MFDS drugMeditoxin Inj.2006-03-16Drug · Prescription · Approval200600841
Clinical trials
data.go.kr19 MFDS clinical trial authorisations · 2012–2021 (Phase 1 8 · Phase 3 7 · Phase 2 4)
- Phase 3MT9212021-06-16
10 trial sites
- Phase 2MT9212019-07-25
12 trial sites
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2019-04-17
7 trial sites
- Phase 1MT9212018-06-22
1 trial site
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-05-11
13 trial sites
- Phase 1MBA-P012018-03-30
1 trial site
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-02-05
4 trial sites
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-01-24
1 trial site
- Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-12-28
2 trial sites
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-10-31
4 trial sites
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-08-18
1 trial site
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-07-10
3 trial sites
Show 7 more
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-05-02
6 trial sites
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-04-03
3 trial sites
- Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2013-12-26
2 trial sites
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2013-09-26
1 trial site
- Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-08-03
4 trial sites
- Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-07-24
1 trial site
- Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-07-11
3 trial sites
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIOAI-SearchBot2
Measured since Aug 26, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Founded 1986, KONEX-listed since 2022, BASKHANBIOPharma makes drugs and medical devices for use before and after surgery.
KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.
KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.
Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition